RxDoctor Payments Data

Chelsea Przydzial, PA

Physician Assistant · Raleigh, NCNPI 1891232344

Payments from drug & device makers

$1,668in general payments, 2019–2025

Across 80 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$450
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$287
  • Collegium Pharmaceutical, Inc.$255
  • Scilex Pharmaceuticals Inc.$216
  • Indivior Inc.$100
  • AbbVie$85
  • plus $273 from 6 others

What the payments were for

  • Food & beverage$1,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,668 in reported general payments places this provider in the 75th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,759
Medicare patients
137
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate151$110,665
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen401$83,690
OxycontinOxycodone Hcl114$81,529
ProlateOxycodone Hcl/Acetaminophen11$33,432
BelbucaBuprenorphine Hcl31$26,956
Fentanyl129$25,819
RelistorMethylnaltrexone Bromide11$24,114
MovantikNaloxegol Oxalate39$17,927
Oxymorphone Hcl ErOxymorphone Hcl22$15,953
Oxycodone Hcl630$12,362
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$11,591
Buprenorphine36$10,367
Hysingla ErHydrocodone Bitartrate13$10,206
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen231$10,189
Morphine Sulfate ErMorphine Sulfate255$10,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$255$137,621182 claims
Forte Bio-pharma LLCProlate$450$33,43211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$287$24,11411 claims
Redhill Biopharma Inc.Movantik$71$17,92739 claims
AbbVieLinzess$85$9,27716 claims
Scilex Pharmaceuticals Inc.Ztlido$216$8,84715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →